David Long, DPM
Podiatrist · Paris, TNNPI 1558455014
Payments from drug & device makers
What this record shows
Arthrex accounts for 65.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $537 and has fallen 95.4% since, to $25 in 2025. That places this record below the midpoint for podiatrist clinicians in TN, where the typical reported total is $745.
Across 26 payments — averaging $28.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$486
- Amgen$55
- Pacira Pharmaceuticals Incorporated$51
- Acera Surgical, Inc.$30
- Medtronic$25
- Heraeus Medical, LLC.$24
- plus $67 from 5 others
What the payments were for
- Travel & lodging$32544%
- Food & beverage$41356%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 13 | $486 |
| Amgen(2 entities) | 3 | $55 |
| Pacira Pharmaceuticals Incorporated | 2 | $51 |
| Acera Surgical, Inc. | 1 | $30 |
| Medtronic | 1 | $25 |
| Heraeus Medical, LLC. | 1 | $24 |
| Heron Therapeutics, Inc. | 1 | $20 |
| Organogenesis Inc. | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Bioventus LLC | 1 | $12 |
| Orthofix Medical, Inc. | 1 | $8 |
How this compares
$738 in reported general payments places this provider in the 45th percentile of 105 podiatrist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 25 | $599 |
| Ketoconazole | 26 | $517 |
| Colchicine | 21 | $149 |
| Mupirocin | 19 | $140 |
| Cephalexin | 29 | $84 |
| Gabapentin | 16 | $73 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $51 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $45 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Paris
- Lindsay FoustParis$9K
- Jeffrey LovelandSparta$809K
- Michael KingNashville$190K
- Penninah KumarMt Juliet$72K
- James HarrisTrenton$49K
- Matthew NeuhausSmyrna$33K
- Paul HutchisonMemphis$17K
- Sam BazrafshanChattanooga$16K
- Abshan MalikKnoxville$13K
- Christopher HendrixBartlett$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.